Stock Earnings 0 analysts rank BMRN stock as an Overweight The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
Analysts Viewpoint Biomarin Pharmaceutical Inc (BMRN) receives an Overweight rating from Morgan Stanley In a filing, Biomarin Pharmaceutical Inc revealed its GVP, Chief Accounting Officer Burkhart Erin unloaded Company’s shares for reported $0.11
Analysts Viewpoint Taking a Closer Look At Biomarin Pharmaceutical Inc (BMRN) Following Its Recent Trade In a filing, Biomarin Pharmaceutical Inc revealed its GVP, Chief Accounting Officer Burkhart Erin unloaded Company’s shares for reported $0.11